Search Results - "Locatelli, Silvia L"

The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma by Ortona, Elena, Locatelli, Silvia L, Pagano, Maria Teresa, Ascione, Barbara, Careddu, Giuseppa, Dupuis, Maria Luisa, Marconi, Matteo, Carlo-Stella, Carmelo, Malorni, Walter, Matarrese, Paola, Pierdominici, Marina

“…About 40% of patients with diffuse large cell lymphoma (DLBCL) still have a poor prognosis. Additionally, DLBCL patients treated with doxorubicin are at risk…”
Get full text

YM155 sensitizes triple‐negative breast cancer to membrane‐bound TRAIL through p38 MAPK‐ and CHOP‐mediated DR5 upregulation by Pennati, Marzia, Sbarra, Stefania, De Cesare, Michelandrea, Lopergolo, Alessia, Locatelli, Silvia L., Campi, Elisa, Daidone, Maria Grazia, Carlo‐Stella, Carmelo, Gianni, Alessandro M., Zaffaroni, Nadia

“…Because available treatments have limited efficacy in triple‐negative breast cancer (TNBC), the identification of new therapeutic strategies to improve…”
Get full text

Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis by Palagano, Eleonora, Muggeo, Sharon, Crisafulli, Laura, Tourkova, Irina L., Strina, Dario, Mantero, Stefano, Fontana, Elena, Locatelli, Silvia L., Monari, Marta, Morenghi, Emanuela, Carlo-Stella, Carmelo, Barnett, John B., Blair, Harry C., Vezzoni, Paolo, Villa, Anna, Sobacchi, Cristina, Ficara, Francesca

“…Autosomal recessive osteopetrosis is a rare skeletal disorder with increased bone density due to a failure in osteoclast bone resorption. In most cases, the…”
Get full text

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530 by Locatelli, Silvia L, Careddu, Giuseppa, Serio, Simone, Consonni, Francesca M, Maeda, Akihiro, Viswanadha, Srikant, Vakkalanka, Swaroop, Castagna, Luca, Santoro, Armando, Allavena, Paola, Sica, Antonio, Carlo-Stella, Carmelo

“…Tumor-associated macrophages (TAMs) and the hyperactivation of the PI3K/AKT pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease…”
Get full text

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells by Carlo-Stella, Carmelo, Locatelli, Silvia L, Giacomini, Arianna, Cleris, Loredana, Saba, Elena, Righi, Marco, Guidetti, Anna, Gianni, Alessandro M

“…The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including…”
Get full text

FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress by Ronca, Roberto, Ghedini, Gaia C, Maccarinelli, Federica, Sacco, Antonio, Locatelli, Silvia L, Foglio, Eleonora, Taranto, Sara, Grillo, Elisabetta, Matarazzo, Sara, Castelli, Riccardo, Paganini, Giuseppe, Desantis, Vanessa, Cattane, Nadia, Cattaneo, Annamaria, Mor, Marco, Carlo-Stella, Carmelo, Belotti, Angelo, Roccaro, Aldo M, Presta, Marco, Giacomini, Arianna

“…Multiple myeloma, the second most common hematologic malignancy, frequently relapses because of chemotherapeutic resistance. Fibroblast growth factors (FGF)…”
Get full text

Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy by Pierdominici, Marina, Maselli, Angela, Locatelli, Silvia L, Ciarlo, Laura, Careddu, Giuseppa, Patrizio, Mario, Ascione, Barbara, Tinari, Antonella, Carlo-Stella, Carmelo, Malorni, Walter, Matarrese, Paola, Ortona, Elena

“…Although Hodgkin lymphoma (HL) is curable with current therapy, at least 20% of patients relapse or fail to make complete remission. In addition, patients who…”
Get full text

A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study by Carlo-Stella, Carmelo, Delarue, Richard, Scarfo, Lydia, Barde, Prajak J., Nair, Ajit, Locatelli, Silvia L., Morello, Lucia, Magagnoli, Massimo, Vakkalanka, Swaroop, Viswanadha, Srikant, Ferreri, Andrés J.M.

“…Tenalisib (RP6530) is a novel, highly specific, dual phosphoinositide-3 kinases (PI3K) δ/γ inhibitor with nano-molar potency. This was a phase I, open-label,…”
Get full text

Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders by Pierdominici, Marina, Barbati, Cristiana, Vomero, Marta, Locatelli, Silvia L., Carlo‐Stella, Carmelo, Ortona, Elena, Malorni, Walter

“…Autophagy represents a key mechanism of cytoprotection that can be activated by a variety of extracellular and intracellular stresses and allows the cell to…”
Get full text

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases by Guidetti, Anna, Carlo-Stella, Carmelo, Locatelli, Silvia L, Malorni, Walter, Mortarini, Roberta, Viviani, Simonetta, Russo, Domenico, Marchianò, Alfonso, Sorasio, Roberto, Dodero, Anna, Farina, Lucia, Giordano, Laura, Di Nicola, Massimo, Anichini, Andrea, Corradini, Paolo, Gianni, Alessandro M

“…To evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. Patients with relapsed and…”
Get full text

Phase II study of sorafenib in patients with relapsed or refractory lymphoma by Guidetti, Anna, Carlo-Stella, Carmelo, Locatelli, Silvia L., Malorni, Walter, Pierdominici, Marina, Barbati, Cristiana, Mortarini, Roberta, Devizzi, Lilli, Matteucci, Paola, Marchianò, Alfonso, Lanocita, Rodolfo, Farina, Lucia, Dodero, Anna, Tarella, Corrado, Di Nicola, Massimo, Corradini, Paolo, Anichini, Andrea, Gianni, Alessandro M.

“…Summary The safety and activity of the multikinase inhibitor sorafenib were investigated in patients with relapsed or refractory lymphoproliferative disorders…”
Get full text

Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia by Guidetti, Anna, Carlo‐Stella, Carmelo, Ruella, Marco, Miceli, Rosalba, Devizzi, Lilli, Locatelli, Silvia L., Giacomini, Arianna, Testi, Adele, Buttiglieri, Stefano, Risso, Alessandra, Mariani, Luigi, Di Nicola, Massimo, Passera, Roberto, Tarella, Corrado, Gianni, Alessandro M.

“…BACKGROUND: Because the long‐term toxicity of myeloablative radioimmunotherapy remains a matter of concern, the authors evaluated the hematopoietic damage and…”
Get full text

Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells by Giacomini, Arianna, Righi, Marco, Cleris, Loredana, Locatelli, Silvia L., Mitola, Stefania, Daidone, Maria Grazia, Gianni, Alessandro M., Carlo-Stella, Carmelo

“…The proapoptotic death receptor 5 (DR5) expressed by tumor associated endothelial cells (TECs) mediates vascular disrupting effects of human CD34 + cells…”
Get full text

Abstract 2420: The dual PI3K δ/γ inhibitor RP6530 in combination with Brentuximab Vedotin (SGN-35) synergistically induces cell death via inhibition of tubulin polymerization in Hodgkin lymphoma cell lines by Locatelli, Silvia L., Careddu, Giuseppa, Viswanadha, Srikant, Vakkalanka, Swaroop, Castagna, Luca, Santoro, Armando, Carlo-Stella, Carmelo

“…Abstract Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL). Expression of…”
Get full text

The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts by Locatelli, Silvia L, Tartari, Silvia, Castagna, Luca, Mazza, Rita, Viswanadha, Srikant, Sportelli, Peter, Vakkalanka, Swaroop, Santoro, Armando, Carlo-Stella, Carmelo

“…INTRODUCTION: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL), suggesting that…”
Get full text

Abstract 4711: The PI3K-δ inhibitor TGR-1202 in combination with Brentuximab Vedotin (SGN-35) synergistically induces G2/M phase arrest and cell death via inhibition of tubulin polymerization in Hodgkin lymphoma cell lines by Locatelli, Silvia L., Tartari, Silvia, Castagna, Luca, Rubino, Luca, Viswanadha, Srikant, Sportelli, Peter, Santoro, Armando, Carlo-Stella, Carmelo

“…Abstract Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL), suggesting that…”
Get full text

Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) by Locatelli, Silvia L, Papait, Roberto, Careddu, Giuseppa, Koschorke, Ada, Stirparo, Giuliano G, Balzarotti, Monica, Castagna, Luca, Santoro, Armando, Carlo-Stella, Carmelo

“…▪ INTRODUCTION: Lenalidomide monotherapy exerts clinical activity in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) with better response rate and…”
Get full text

The PI3K-δ Inhibitor TGR-1202 In Combination With Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization In Hodgkin Lymphoma Cell Lines by Locatelli, Silvia L, Tartari, Silvia, Rubino, Luca, Brusamolino, Ercole, Castagna, Luca, Sportelli, Peter, Santoro, Armando, Carlo-Stella, Carmelo

“…The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL), suggesting that TGR-1202, a novel…”
Get full text

YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation: YM155 enhances mTRAIL-induced apoptosis in TNBC by Pennati, Marzia, Sbarra, Stefania, De Cesare, Michelandrea, Lopergolo, Alessia, Locatelli, Silvia L., Campi, Elisa, Daidone, Maria Grazia, Carlo-Stella, Carmelo, Gianni, Alessandro M., Zaffaroni, Nadia

Get full text

The histone Deacetylase Inhibitor Givinostat in Combination with Sorafenib Induces Reactive Oxygen Species (ROS) Generation and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts by Locatelli, Silvia L, Guidetti, Anna, Cleris, Loredana, Tartari, Silvia, Gianni, Alessandro M., Anichini, Andrea, Carlo-Stella, Carmelo

“…Abstract 3711 Patients with refractory or relapsed classical Hodgkin Lymphoma (cHL) represent an unmet medical need and would benefit from the development of…”
Get full text